A detailed history of Martingale Asset Management L P transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Martingale Asset Management L P holds 53,327 shares of VRTX stock, worth $21.8 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
53,327
Previous 62,672 14.91%
Holding current value
$21.8 Million
Previous $29.4 Million 15.57%
% of portfolio
0.58%
Previous 0.64%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $4.3 Million - $4.73 Million
-9,345 Reduced 14.91%
53,327 $24.8 Million
Q2 2024

Aug 12, 2024

SELL
$392.81 - $485.53 $2.87 Million - $3.55 Million
-7,316 Reduced 10.45%
62,672 $29.4 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $2.64 Million - $2.88 Million
-6,464 Reduced 8.45%
69,988 $29.3 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $1.66 Million - $1.99 Million
-4,845 Reduced 5.96%
76,452 $31.1 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $200,878 - $215,301
-594 Reduced 0.73%
81,297 $28.3 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $626,010 - $700,652
-1,991 Reduced 2.37%
81,891 $28.8 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $197,411 - $225,200
697 Added 0.84%
83,882 $26.4 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $700,969 - $788,590
-2,453 Reduced 2.86%
83,185 $24 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $5.36 Million - $5.98 Million
19,586 Added 29.65%
85,638 $24.8 Million
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $3.14 Million - $3.91 Million
13,356 Added 25.35%
66,052 $18.6 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $9.23 Million - $10.9 Million
41,677 Added 378.23%
52,696 $13.8 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $1.01 Million - $1.27 Million
5,687 Added 106.66%
11,019 $2.42 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $14.6 Million - $16.3 Million
-80,314 Reduced 93.77%
5,332 $967,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $3.65 Million - $4.31 Million
-19,484 Reduced 18.53%
85,646 $17.3 Million
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $7.76 Million - $9.05 Million
37,505 Added 55.46%
105,130 $22.6 Million
Q4 2020

Feb 10, 2021

SELL
$207.01 - $276.09 $12.5 Million - $16.7 Million
-60,455 Reduced 47.2%
67,625 $16 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $10.8 Million - $12.8 Million
42,151 Added 49.05%
128,080 $34.9 Million
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $16.1 Million - $21.1 Million
71,259 Added 485.75%
85,929 $24.9 Million
Q1 2020

May 11, 2020

BUY
$199.77 - $247.81 $1.89 Million - $2.34 Million
9,452 Added 181.14%
14,670 $3.49 Million
Q4 2019

Feb 10, 2020

SELL
$166.71 - $223.91 $999,426 - $1.34 Million
-5,995 Reduced 53.46%
5,218 $1.14 Million
Q3 2019

Nov 13, 2019

SELL
$166.23 - $187.09 $432,198 - $486,434
-2,600 Reduced 18.82%
11,213 $1.9 Million
Q1 2019

May 08, 2019

BUY
$163.73 - $194.7 $491 - $584
3 Added 0.02%
13,813 $0
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $30,685 - $38,826
-202 Reduced 1.44%
13,810 $2.29 Million
Q3 2018

Nov 09, 2018

BUY
$167.73 - $192.74 $519,962 - $597,494
3,100 Added 28.41%
14,012 $0
Q2 2018

Aug 09, 2018

SELL
$145.72 - $169.96 $319,855 - $373,062
-2,195 Reduced 16.75%
10,912 $0
Q1 2018

May 11, 2018

SELL
$151.6 - $177.13 $105,968 - $123,813
-699 Reduced 5.06%
13,107 $0
Q4 2017

Feb 12, 2018

SELL
$137.28 - $155.55 $68,502 - $77,619
-499 Reduced 3.49%
13,806 $0
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $2.12 Million - $2.32 Million
14,305
14,305 $2.18 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.